European Human Genetics Conference 2007 June 16 – 19, 2007 ...
European Human Genetics Conference 2007 June 16 – 19, 2007 ...
European Human Genetics Conference 2007 June 16 – 19, 2007 ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Genomics, technology, bioinformatics<br />
Leiden, The Netherlands, 5 Erasmus MC, Rotterdam, The Netherlands.<br />
The panoply of human globin gene mutation detection methods has become<br />
significantly enriched with the advent of microarray-based genotyping<br />
platforms. So far, a handful of microarray-based methods have<br />
been described for mutation screening in the human globin genes region,<br />
namely a microelectronic array, arrayed primer extension-based<br />
(APEX) systems and microarrays involving tagged single-base extension<br />
(SBE) with hybridization to universal glass microarrays. We report<br />
here a new flow-through microarray for human β-globin gene mutation<br />
detection. This microarray has a porous surface and uses Al 2 O 3 as<br />
a solid support, which allows not only diffusion-independent binding<br />
kinetics, but also monitoring of hybridization of the extended primers<br />
in real-time by repeated cycling of the sample through the array. The<br />
hybridization process is therefore fully reaction-rate limited and completed<br />
within a few minutes. The microarray is read by a dedicated<br />
instrument (PamStation TM ), while data are analyzed using specialized<br />
software. The microarray is being developed to screen for both causative<br />
β-globin gene mutations leading to β-thalassemia and associated<br />
SNPs for haplotype analysis. For this reason, 20 different β-globin<br />
gene mutations and 15 SNPs located in the human β-globin locus can<br />
be currently addressed using this platform (Phase I) with the ultimate<br />
goal to expand the microarray’s capacity to screen for a total of 108<br />
causative mutations and 30 SNPs (Phase II). Taken together the low<br />
analysis costs (i.e. 50-70€ per patient), this platform might develop into<br />
an option for numerous potential applications from human molecular<br />
diagnostics to pre-implantation genetic diagnosis and non-invasive<br />
prenatal diagnosis of hemoglobinopathies.<br />
P1274. Microarray analysis of bone metabolism genes in<br />
patients with osteoporosis<br />
D. N. Ghorab 1 , M. V. Moskalenko 1 , A. S. Glotov 2 , E. S. Vashukova 2 , L. B. Polushkina<br />
2 , T. E. Ivaschenko 2 , M. V. Assev 2 , V. G. Pinelis 3 , V. S. Baranov 2 ;<br />
1 Saint-Petersburg State University, Saint-Petersburg, Russian Federation, 2 Ott’s<br />
Institute of Obstetrics & Gynecology RAMS, Saint-Petersburg, Russian Federation,<br />
3 Scientific Center of Children Health RAMS, Moscow, Russian Federation.<br />
Osteoporosis is a complex desease with a strong genetic component.<br />
Various genes encoding bone associated proteins, cytokines and receptors,<br />
have been shown to contribute to genetic basis of the disease.<br />
For analysis following loci were selected: Col1a1 (-<strong>19</strong>97 G/T, 1245 G/<br />
T), BGP (-<strong>19</strong>8 C/T), IL-6 (-174 C/T), TNFα (-308 G/A), VDR (-3731<br />
A/G, 6<strong>19</strong>68 C/T), ER (36627 C/T, 36673 A/G) and GR (N363S A/G).<br />
These loci feature significant genetic polymorphism, and are thought<br />
to be associated with genetic predisposition to osteoporosis. A genetic<br />
study of predisposition to the osteoporosis is believed to extend our<br />
knowledge about the disease and to determine the optimal terms for<br />
antiosteoporotic therapies.<br />
We have started to introduce in practice a new molecular approach,<br />
developed with using of multiplex PCR followed by allele-specific hybridization<br />
on biochip for SNPs detection. Amplified DNA with fluorescent<br />
labels was hybridized with oligonucleotide DNA probes immobilized<br />
in gel pads on a biochip. The efficiency of the protocol was tested<br />
in our laboratory. The results showed 100% concordance between the<br />
biochip-based approach and the established PCR protocol.<br />
The genotyping procedure, which is faster, reliable and can be used for<br />
rapid screening on the biochip is suggested for the analysis of genetic<br />
predisposition to multifactorial diseases, including osteoporosis.<br />
P1275. A new method for separation and characterization of<br />
small RNA by On-Chip Electrophoresis<br />
R. Salowsky1 , C. Tissot1 , M. Valer2 , Y. Filaudeau3 ;<br />
1 2 Agilent Technologies, Waldbronn, Germany, Agilent Technologies, Inc., Santa<br />
Clara, CA, United States, 3Agilent Technologies, Nice, France.<br />
MicroRNAs have just been recognized to play important roles in regulation<br />
in the genomes of animals and plants. To understand and describe<br />
their functional roles many questions still have to be answered.<br />
A major drawback for current experiments is the lack of adequate analytical<br />
methods for the analysis of small RNA samples and understanding<br />
on how RNA integrity and different purification protocols affect its<br />
qualitative and quantitative analysis.<br />
Here we describe a novel Microfluidic assay that is able to perform<br />
very sensitive high resolution analyses of small RNA samples on a<br />
commercial lab-on-a-chip platform commonly used for RNA QC analysis.<br />
The assay delivers information about size and concentration of<br />
small RNA species like miRNA, siRNA, t-RNA etc, in the range from<br />
10 to 150nt. Purified or enriched small RNA fractions, as well as total<br />
RNA samples with miRNA concentrations down to 50 pg/µl can be<br />
analyzed.<br />
Verification of quality and quantity of miRNA after extraction protocols<br />
is a major application for this Assay. Capability for separation and efficient<br />
detection of both single- and double strand nucleic acids widens<br />
the range for sensitive analysis with this On-Chip assay.<br />
P1276. Functional assessment of DNA loop repair in human<br />
nuclear extracts<br />
S. Jaroudi, J. C. Harper, S. B. SenGupta;<br />
University College London, London, United Kingdom.<br />
Introduction: Mismatch repair (MMR) corrects small base mismatches<br />
and insertion/deletion loops that arise within microsatellite repeats.<br />
Current repair assays predominantly rely on cloning techniques. We<br />
have designed an alternative functional assay for MMR.<br />
Methods: Heteroduplex DNA molecules containing an insertion loop<br />
were created by hybridisation of purified complementary single strands<br />
of DNA from PCR products of the DMPK1 trinucleotide repeat locus<br />
from separate homozygous samples. A nick was introduced 5’ to the<br />
heterology to direct the repair to a specific strand. Heteroduplex constructs<br />
were exposed to nuclear extracts from HeLa (MMR efficient)<br />
and LoVo (MSH2 deficient) cells to repair the insertion loop. Using<br />
semi-quantitative fluorescence analysis, the ratio of fluorescence from<br />
the nicked strand and the complementary un-nicked strand could be<br />
determined (R-value). Repair efficiency was assessed by comparing<br />
R-values before and after exposure to nuclear extracts.<br />
Results: Exposure of heteroduplexes to HeLa nuclear extracts resulted<br />
in change in the R-value, indicative of repair. Repair was independent<br />
of loop size (2, 21 and 24-bases) and nick directed. Little or no<br />
repair was detected for 2-base loops in absence of a 5’-nick, however,<br />
for larger loops repair was nick independent. Change in the R-value<br />
was proportional to the duration of exposure to nuclear extracts. LoVo<br />
nuclear extracts showed little repair for large loops and no repair was<br />
detected for the 2-base loops.<br />
Conclusion: This construct is easily generated and modified to vary the<br />
size of the insertion loop. The same approach can be used to assess<br />
repair of base-base mismatches.<br />
P1277. The mitochondrial DNA content per cell in human cord<br />
blood leukocytes gradually decreases during gestation<br />
M. Pejznochova, M. Tesarova, T. Honzik, H. Hansikova, M. Magner, J. Zeman;<br />
Dept. of Pediatrics, Faculty of Medicine, Charles University, Prague, Czech<br />
Republic.<br />
Most diseases in premature neonates are secondary to immaturity of<br />
various organ systems. In addition, the inadequate capacity of mitochondrial<br />
energy production may play an important role in the neonatal<br />
morbidity. Isolated human cord blood leukocytes (HCBL) contribute<br />
very little to the overall metabolic turnover, but they may serve as easily<br />
available marker cells for studying the changes of mtDNA amount<br />
during fetal development. Therefore the aim of our study was to analyze<br />
the amount of mitochondrial DNA in HCBL during the gestation.<br />
HCBL were isolated from blood samples of 107 neonates born between<br />
25 th and 41 st week of gestation. Blood samples were obtained<br />
after the delivery from placental part of umbilical cord. The mtDNA<br />
amount was analyzed by the real-time PCR method on the instrument<br />
Chromo4 (Bio-Rad) using SybrGreen I.<br />
The significant negative correlations were found between the relative<br />
mtDNA amount in HCBL and gestational age (r = - 0,54; p < 0,01) and<br />
birth weight (r = - 0,43; p < 0,01), respectively.<br />
The results revealed that the mtDNA content per cell decreases in<br />
HCBL with onward fetal development. This may be explained by gradual<br />
shift of the hematopoiesis from fetal liver to bone marrow during the<br />
second half of pregnancy presumably accompanied by decreasing cell<br />
volume of HCBL as it was shown similarly in red blood cells.<br />
This work was supported by grant GACR 303/03/H065.<br />
1